{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T06:03:38Z","timestamp":1769234618565,"version":"3.49.0"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the use of cyclooxygenase\u20102 inhibitors in patients receiving low\u2010dose\u2010rate brachytherapy for prostate cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 310 patients with prostate cancer (cT1c\u20103aN0M0) who received low\u2010dose\u2010rate brachytherapy between May 2010 and July 2013 were enrolled and allocated to one of the two treatment groups (tamsulosin alone 0.2\u00a0mg\/day for 6\u00a0months <jats:italic>vs<\/jats:italic> tamsulosin 0.2\u00a0mg\/day for 6\u00a0months plus celecoxib 200\u00a0mg\/day for 3\u00a0months). The primary end\u2010point was the chronological change in international prostate symptom score, and the number of patients was assessed for the primary end\u2010point. Biochemical recurrence\u2010free, cancer\u2010specific survival and overall survival rates 5\u00a0years after the last patient received low\u2010dose\u2010rate brachytherapy were retrospectively examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median follow\u2010up period after low\u2010dose\u2010rate brachytherapy was 72.0\u00a0months (range 3\u201399\u00a0months). A total of 12 (3.9%) patients experienced biochemical recurrence. The biochemical recurrence\u2010free rate in the celecoxib group (5\u2010year biochemical recurrence\u2010free rate 98.5%) was significantly better (log\u2013rank test <jats:italic>P<\/jats:italic>\u00a0=\u00a00.023, 95% confidence interval 0.07\u20130.63, hazard ratio 0.20) than that in the tamsulosin group (5\u2010year biochemical recurrence\u2010free rate 93.4%). None of the patients died from prostate cancer. However, 14 (4.5%) patients died of other causes. No significant difference was observed in terms of overall survival between the celecoxib and tamsulosin groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The combination of cyclooxygenase\u20102 inhibitor and low\u2010dose\u2010rate brachytherapy can contribute to a better biochemical control of prostate cancer.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.14294","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T08:24:33Z","timestamp":1593159873000},"page":"755-759","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biochemical control of the combination of cyclooxygenase\u20102 inhibitor and <sup>125<\/sup>I\u2010brachytherapy for prostate cancer: Post hoc analysis of an open\u2010label controlled randomized trial"],"prefix":"10.1111","volume":"27","author":[{"given":"Yasushi","family":"Nakai","sequence":"first","affiliation":[{"name":"Departments of Department of Urology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Asakawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Anai","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Morizawa","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunta","family":"Hori","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Owari","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiho","family":"Ohbayashi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Yamaki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Departments of Department of Urology Nara Medical University Kashihara Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"198","article-title":"Cyclooxygenase\u20102 expression in human esophageal carcinoma","volume":"59","author":"Zimmermann KC","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_7_3_1","first-page":"1276","article-title":"Expression of cyclooxygenase\u20102 in human gastric caricinoma","volume":"57","author":"Ristim\u00e4ki A","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_7_4_1","first-page":"3785","article-title":"Expression of cyclooxygenase\u20101 and \u20132 in human colorectal cancer","volume":"55","author":"Sano H","year":"1995","journal-title":"Cancer Res."},{"key":"e_1_2_7_5_1","first-page":"3761","article-title":"Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas","volume":"58","author":"Hida T","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.06.014"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70280-2"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1208"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000092239.98832.52"},{"key":"e_1_2_7_10_1","first-page":"2998","article-title":"A selective cyclooxygenase\u20102 inhibitor, NS\u2010398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase\u20102","volume":"7","author":"Pyo H","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.01.019"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-13-1"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10827.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.01.006"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rry101"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2017.12.004"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.5114\/jcb.2019.88142"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2009.08.006"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2011.03.007"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.09.048"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou155"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.92013"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2485-9"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2010.10.016"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12166"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.07.064"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2019.10.004"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.14294","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.14294","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.14294","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.14294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T16:17:48Z","timestamp":1693930668000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.14294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/iju.14294"],"URL":"https:\/\/doi.org\/10.1111\/iju.14294","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"2020-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}